Genmab — Marts 2014
-
han vil have option på at co-own et program af GENs valg. Det kan være en tung pille at sluge for big pharma
-
hvis 1-2 programmer er mega gode i Duobody og Hexa vil de have ind i aftaler at de har option på at købe sig ind 50/50 i de mest lovende programmer. Vildt spændende
-
late cycle arzerra FDA - very positive. Hopefully broad label
-
spændende kommentarer omkring FDA processen!!!!
-
Bowersnu
-
guidance omkring arzerra 1st line
-
kommentar omkring emea meeting - omkring bendamustine
-
hexa - how far along are they - clinical stage?
-
no delays
-
emea - ongoing dialogue, working hard on broad label, no delays
-
limited study with phase II bendamustine, trying to include, nothing further to addd
-
hexa - r&d trying to let other comanies "sniff", data generated will end up in the textbooks because of the results
-
new generation of antibodies
-
after empower antiboides with hexa - good idea to bring back into clinic
-
will try to collect programs to GEN pipeline - but will see combination
-
enten kan partneren selv bringe dem tilbage eller gen tager stofferne ind i deres egen pipeline
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind